OncoMatch/Clinical Trials/NCT05961761
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
Is NCT05961761 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Propranolol and Pembrolizumab for soft tissue sarcoma adult.
Treatment: Propranolol · Pembrolizumab — The goal of this phase 2 clinical trial is to test efficacy and tolerability of combining propranolol and pembrolizumab in patients with advanced angiosarcoma or undifferentiated pleomorphic sarcoma. The main questions aims to answer: * Primary: determine the progression-free survival rate (PFSR) at 3 months Secondary: determine the objective response rate (ORR), duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS). Ensure the safety and tolerability, Determine Quality of Life (QoL) • Exploratory: Characterize the TME Participants will be asked to ensure * Baseline biopsy and further optional biopsies * Treatment propranolol 40 mg BID and pembrolizumab 2 mg/kg Q3 weeks * Evaluation, blood counts, QoL and blood samples for biomarkers according to schedule
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: cytotoxic chemotherapy — first line
who has progressed/failed to provide clinical benefit on first line standard chemotherapy
Cannot have received: anti-PD-1 therapy
Have received any previous systemic therapy targeting the PD-1/PDL-1 signaling pathway or other immune checkpoint inhibitors
Cannot have received: beta blocker (propranolol)
Have received propranolol within 4 weeks prior to treatment
Cannot have received: radiation therapy
Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks
Cannot have received: cytotoxic chemotherapy
Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks
Cannot have received: targeted small molecule therapy
Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks
Cannot have received: monoclonal antibody
Prior to study day one received radiation therapy, chemotherapy or targeted small molecule therapy within 2 weeks and/or monoclonal antibody treatment within 4 weeks
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1 x 10⁹/L; Platelet count ≥ 75 x 10⁹/L
Kidney function
Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (using the Cockcroft-Gault formula)
Liver function
Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L); AST/ALT ≤ 5 x ULN
Patients must have normal organ and marrow function as defined below: * Absolute neutrophil count (ANC) ≥ 1 x 10⁹/L * Platelet count ≥ 75 x 10⁹/L * Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) (patients with Gilbert's Syndrome must have a total bilirubin ≤ 50 mmol/L) * Aspartate transaminase (AST)/Alanine transaminase (ALT) ≤ 5 x ULN * Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (using the Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05961761 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, beta blocker, radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages